The discontinuation is not due to safety or efficacy reasons, according to the Company. The other tablet strengths — 5mg, 10mg, 20mg — will continue to be available in 30-count bottles.
Levitra, a phosphodiesterase type 5 (PDE5) inhibitor, is indicated to treat erectile dysfunction. The inhibition of PDE5 enhances erectile function by increasing the amount of cyclic guanosine monophosphate (cGMP). The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection.
Levitra should be taken approximately 60 minutes before sexual activity.
For more information call (888) 842-2937 or visit FDA.gov.